ロード中...
HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7878396/ https://ncbi.nlm.nih.gov/pubmed/33584306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.621054 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|